Selling AI to Healthcare: The BAA Is the Real Gate

If you are selling AI into healthcare, the business associate agreement is the gate, and it is a hard one. A hospital or health system that touches protected health information cannot legally use a vendor who will not sign a BAA and stand behind it. This is not a preference like SOC 2, where a young vendor can sometimes negotiate around the gap. It is a legal requirement. No BAA, no deal, no exceptions. The demo does not matter until you can clear this bar, and founders who treat HIPAA as a later-stage detail waste months chasing deals that were never available to them.

Here is what the BAA actually requires and why it decides the deal.

why the BAA is a hard requirement, not a preference

HIPAA makes a covered entity, the hospital, legally responsible for how its vendors handle protected health information. A business associate agreement is the contract that passes specific obligations to you and makes you accountable for them. Without a signed BAA, the covered entity is not permitted to share PHI with you at all.

That is what makes it different from every other assurance document. A security questionnaire can be negotiated. SOC 2 can sometimes be deferred, as I cover in whether your AI startup needs SOC 2. The BAA cannot. If your product touches PHI and you will not or cannot sign one that means it, the deal is legally impossible, and pretending otherwise wastes everyone's time.

what signing a BAA actually commits you to

Signing a BAA is not a formality, it is a set of enforceable obligations. You commit to safeguarding PHI, limiting its use to the permitted purpose, reporting breaches on a defined timeline, and ensuring your own subprocessors are equally bound. Sign it lightly and you have taken on liability you may not be equipped to carry.

Before you sign, your infrastructure has to actually meet the commitment. Encryption of PHI at rest and in transit. Access controls and audit logging on every touch of the data. A real breach response process, not an aspiration. And critically, every subprocessor in your chain that could see PHI must itself be under a BAA with you. Your subprocessor list is not just documentation here, it is a compliance chain, and one uncovered link breaks it. If you use a model provider that will not sign a BAA, you cannot route PHI through it, full stop. Know where enterprise data goes in your own system down to the subprocessor level before you sign anything.

the assurance work that surrounds the BAA

The BAA is the gate, but clearing it requires the full assurance package around it. Healthcare buyers layer their own security review on top of the legal requirement, and it is a thorough one.

You will face a heavy security questionnaire, often industry-specific. Have your answers prepared and reusable so the volume does not stall you. You need to prove where PHI lives and how it is segregated, because data residency and isolation matter more when the data is medical. And you need audit trails that hold up, because a healthcare buyer, and eventually a regulator, will want to see who accessed what and when.

Package all of it in a trust center built for the healthcare buyer, with the BAA terms, HIPAA posture, and audit evidence ready before the first serious conversation.

how to approach healthcare deals without wasting the quarter

Qualify on the BAA first. Before you invest in a healthcare deal, confirm your product and your subprocessor chain can actually support a signed BAA. If a core dependency will not sign one and PHI flows through it, either fix the architecture or do not pursue PHI-touching deals until you can.

Then treat HIPAA as the market-opening feature it is. Regulated industries are the best AI market because the compliance bar keeps casual competitors out. A vendor who can sign a BAA and back it with real controls competes against far fewer alternatives than one selling into an unregulated space.

The founders who win healthcare build for the BAA before they build the pitch. My ventures architect PHI handling and subprocessor coverage up front for exactly this reason, which is why CaseSolo treats regulated-data requirements as a design constraint, not a sales-stage surprise. Clear the BAA gate first, and the healthcare market opens. Ignore it, and the demo never gets a chance.